Tissue Repair & Recovery

TB-500
Thymosin Beta-4 Fragment

TB-500 is the synthetic fragment of Thymosin Beta-4, a naturally occurring protein found in virtually all human and animal cells. Its systemic mechanism sets it apart — effective even when administered away from the site of injury, making it one of the most versatile tissue repair compounds in preclinical research.

Tissue RepairActin RegulationCell MigrationSystemic RecoveryAnti-InflammatoryAngiogenesis

At a Glance

CAS Number
77591-33-4
Molecular Weight
2,112 Da
Amino Acids
43 Amino Acids
Published Studies
80+ studies
Stability
Moderate — cold storage required
Research Status
Extensive preclinical
← Back to Research Library
Overview

TB-500's primary mechanism centers on actin regulation. By sequestering G-actin and upregulating Thymosin Beta-4 expression, it drives cell migration, proliferation, and tissue remodeling throughout the body — not just locally.

Unlike BPC-157, which tends toward localized cytoprotection, TB-500 operates more systemically. It can be administered away from an injury site and still reach the target tissue — a practical advantage that has shaped how researchers design multi-site injury studies.

"TB-500 is the systemic complement to BPC-157's localized action. Together they form the Wolverine Stack — one of the most cited tissue repair combinations in regenerative biology preclinical research."

The two compounds are frequently studied together because their mechanisms cover different biological territory and appear to produce additive outcomes in repair models.

Mechanism of Action

This compound operates through several converging biological pathways, which helps explain the breadth of effects observed across different tissue and metabolic models.

🔬

Actin Sequestration

Binds G-actin via the LKKTET motif, regulating actin polymerization dynamics and enabling accelerated cell migration into damaged tissue.

🩸

Angiogenesis

Promotes new vessel formation by upregulating VEGF and MMP pathways, supporting vascular repair and nutrient delivery to injury sites.

🛡️

Anti-Inflammatory

Downregulates TNF-α, IL-6, and NF-κB signaling, reducing chronic inflammation in musculoskeletal and soft tissue models.

🧬

Tissue Remodeling

Activates fibroblasts and keratinocytes, accelerating collagen deposition and extracellular matrix reorganization in healing tissue.

Key Research Areas

Preclinical and clinical models have investigated this compound across a wide range of physiological contexts and tissue types.

  • Acceleration of muscle, tendon, and ligament repair in transection and crush models
  • Wound healing via enhanced fibroblast and keratinocyte migration
  • Cardiac tissue protection — studied in ischemic event models in rodents
  • Reduction of scar tissue formation and improvement in remodeling quality
  • CNS injury models — early preclinical findings for nerve repair
  • Systemic administration studies — efficacy observed when injected distal to injury
  • Fibrosis reduction in pulmonary and hepatic injury models

The systemic nature of TB-500's action makes it particularly valuable in research designs that can't rely on precise local injection — a practical advantage that has contributed to its popularity.

Frequently Asked Questions
Is TB-500 the same as Thymosin Beta-4?
+
No — TB-500 is the synthetic actin-binding fragment (Ac-LKKTET) of Thymosin Beta-4. It shares the core repair mechanisms but is a distinct peptide with different pharmacokinetics.
Can TB-500 be injected away from the injury site?
+
Yes. This is one of its most researched properties — TB-500 demonstrates systemic activity in preclinical models, reaching the target tissue regardless of injection site.
How does TB-500 compare to BPC-157?
+
TB-500 is more systemic — it works broadly through actin regulation and cell migration. BPC-157 is more localized, via angiogenesis and cytoprotection. They're complementary, which is why they're frequently stacked.
What is the Wolverine Stack?
+
A research combination of BPC-157 and TB-500. The compounds cover different mechanisms — BPC-157's localized effects and TB-500's systemic actin-mediated repair — making them a well-studied pairing.

This overview is strictly educational and based on publicly available scientific literature as of 2026. It does not constitute medical advice. All Helixera Labs products are for laboratory research use only. Not for human or veterinary use. · Helixera Labs LLC © 2026